2020 POSTER PRESENTATIONS

Room: Quayside Foyer

POSTER SESSION A
Presenting Tuesday

Arabian Gulf University
1A.      A Critical Role for the Immune Modulator ISRAA in the Ontogenetic Development of the Brain; Presented by Moiz B.
Erasmus MC Cancer Institute
2A.      TME-Analyzer: A Multi-Dimensional Visualization and Analysis Tool to Capture Immune Contexture in Tumor Tissues; Presented by Hayri E. B.
GlaxoSmithKline
3A.      Epidemiology of Synovial Sarcoma in EU28 Countries; Presented by John F.
Immuneed AB
4A.      Blood-Drug Interactions in Real-Time: Case Study with CLL Patients; Presented by Erika F.
ImmunXperts SA
5A.      The Power of In Vitro Assays to Unleash the Potential of Drug Candidates in Cancer Immunotherapy; Presented by Ellen B.
Max-Delbrueck-Center for Molecular Medicine
6A.      CAR T Cells Directed Against a B Cell Homing Receptor for the Targeting of B Cell Non-Hodgkin's Lymphoma; Presented by Janina P.
National Institutes of Health, National Cancer Institute
7A.      The Combination of the CDK4/6 Inhibitor Palbociclib with mTOR Inhibitors Showed Additivity in the Treatment of HTLV-1 Associated Adult T-Cell Leukemia; Presented by Sarvesh K.
OXGENE Ltd.
8A.      Isolation and Characterisation of EpCAM Specific scFvs Using SLIM Mammalian Display; Presented by Nancy L.
ProQinase GmbH
9A.      SubQperior: An Alternative Implantation Method for Syngeneic Tumor Models; Presented by Holger W.

 

POSTER SESSION B
Presenting Tuesday(evening) – Wednesday(morning)

Agilent Technologies Ireland Ltd.
1B.      Characterising the Metabolic Consequences of T Cell Activation and Immunosuppression; Presented by James H.
Altimmune UK Ltd.
2B.      ALT-702: A Depot-Forming TLR7/8 Agonist Technology to Uncouple Immune-Mediated Efficacy from Systemic Toxicity; Presented by Bertrand G.
Biocytogen
3B.      Rapid Therapeutic Antibody Development Using RenMab Mouse, a Fully Human Antibody Mouse; Presented by Gary N.
ChromoTek GmbH
4B.      Nano-BiTEs: Bispecific T Cell Engagers Based on Nanobodies; Presented by Christian L.
Crown Bioscience UK Ltd.
5B.      Characterization of a Panel of Orthotopic Syngeneic Models Using Bioluminescent Imaging for the Evaluation of Immuno-Oncology Therapies; Presented by Sarah W.
Crown Bioscience, Inc.
6B.      Investigation of the Mechanism of Action of Anti-PD-1 Treatment by Systematic Depletion of Different Immune Cell Populations in Syngeneic Models; Presented by David V.
Hubrecht Organoid Technology Foundation
7B.      Patient Derived Organoid as a Novel Clinical Predictive Platform for Immuno-Oncology; Presented by Soura M.
MaxCyte, Inc.
8B.      Advancing Adoptive Cell Therapies Using Clinically Scalable Engineering of T Cells and NK Cells; Presented by Marianna R.
Panolos Bioscience, Inc.
9B.      A Novel VEGF Decoy Receptor and Its Multi-Paratopic Application; Presented by Hyun-Gul Y.

 

POSTER SESSION C
Presenting Wednesday(afternoon) - Thursday

Centre de Lutte Contre le Cancer Léon Bérard
1C.      Rotavirus Viruses as a Natural RIG-I Agonist to Overcome Resistance to Immune Checkpoint Targeted Therapies; Presented by Sandrine V.
GemPharmatech Co. Ltd.
2C.      BALB/c-hCD3E Transgenic Mice: An Ideal Model for In Vivo Efficacy Study of CD3-Bispecific Antibodies; Presented by Dan W.
GlaxoSmithKline
3C.      Novel Regimens Versus Standard-of-Care in NSCLC: A Phase II, Randomized, Open-Label, Platform Trial Using a Master Protocol; Presented by Louise F.
Hubrecht Organoid Technology Foundation
4C.      Organoids: A Novel Patient Derived Platform for Drug Discovery, Diagnosis and Personalized Medicine; Presented by Farzin P.
IsoPlexis
5C.      Highly Multiplexed, Single-Cell Cytokine Profiling of Immune Cells Enables Functional Biomarkers Across Checkpoint and Combination Therapy; Presented by Peter D.
Kanazawa University
6C.      Serum IL-8 and Eotaxin Concentration Are Correlated with the Gene Expression Profiles of CD4+ Cells in Peripheral Blood of Patients with Colorectal Cancer; Presented by Takuya K.
Swansea University
7C.      Establishment and Implementation of a Highly Effective and Robust Development and Characterisation Platform for ADCs Specific to Ovarian Cancer Targets; Presented by Emenike O.
University of Leeds
8C.      Characterisation of bsAb Higher-Order Structure Using FPOP-LC-MSMS; Presented by Melissa C.
University of Manchester
9C.      Developing Dual CXCR4/ACKR3 (CXCR7) Targeted Theranostic Agents: Potential Applications in Immuno-Oncology; Presented by Abid K.

Japan-Flag Korea-Flag China-Simplified-Flag China-Traditional-Flag